SCHEMBL4200494

SCHEMBL4200494

O=c1c2cccnc2nc(-c2ccc(F)cc2)n1NCc1ccc(F)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
IDO1 P14902 2/20 0.43
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
MAPT P10636 3/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 2/20 0.38
KAT2B Q92831 1/20 0.38
HCAR2 Q8TDS4 1/20 0.37
PDPK1 O15530 3/20 0.37
ABCG2 Q9UNQ0 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
CES2 O00748 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202613 0.88 SMN1; SMN2 (0.48) SMN1; SMN2IDO1MEN1POLBKMT2A
SCHEMBL4199192 0.86 SMN1; SMN2 (0.48) SMN1; SMN2IDO1MEN1POLBKMT2A
SCHEMBL4202602 0.84 SMN1; SMN2 (0.47) SMN1; SMN2IDO1POLBLMNANPSR1
SCHEMBL4233225 0.78 SMN1; SMN2 (0.56) SMN1; SMN2MEN1POLBKMT2AMAPT
SCHEMBL4201010 0.78 SMN1; SMN2 (0.38) SMN1; SMN2MAPTLMNAHTTCES2
SCHEMBL4188985 0.76 MAPT (0.46) SMN1; SMN2IDO1MEN1POLBKMT2A
SCHEMBL4200347 0.75 ALDH1A1 (0.44) SMN1; SMN2IDO1MAPTTP53KAT2B
SCHEMBL4240608 0.74 SMN1; SMN2 (0.66) SMN1; SMN2MEN1POLBKMT2AMAPT
SCHEMBL4194181 0.74 ALDH1A1 (0.41) SMN1; SMN2MEN1POLBKMT2AMAPT
SCHEMBL4205026 0.74 IDO1 (0.42) SMN1; SMN2IDO1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 SMN1; SMN2 3183/4885IDO1 3233/4885MEN1 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.